S Dupuis-Girod

Summary

Affiliation: Hospices Civils de Lyon
Country: France

Publications

  1. doi request reprint ZEB2, a new candidate gene for asplenia
    Linda Pons
    Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Génétique et Centre de référence des anomalies du développement, Bron F 69677, France
    Orphanet J Rare Dis 9:2. 2014
  2. doi request reprint Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output
    Sophie Dupuis-Girod
    Hospices Civils de Lyon, Hopital Louis Pradel, Genetic Department and National Reference Center for Rendu Osler Disease, Bron, France
    JAMA 307:948-55. 2012
  3. ncbi request reprint Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association
    Sophie Dupuis-Girod
    Service de Génétique et Centre de Référence sur la Maladie de Rendu Osler, hôpital de l Hôtel dieu, Lyon, France
    Clin Infect Dis 44:841-5. 2007
  4. doi request reprint Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study
    Sophie Dupuis-Girod
    Service de Génétique et Centre de Référence pour la Maladie de Rendu Osler, Lyon, France
    Liver Transpl 16:340-7. 2010
  5. doi request reprint Hereditary hemorrhagic telangiectasia: from molecular biology to patient care
    S Dupuis-Girod
    Service de Génétique et Centre de Référence National Maladies Rares, maladie de Rendu Osler, Hospices Civils de Lyon, hôpital de l Hôtel dieu, Lyon, France
    J Thromb Haemost 8:1447-56. 2010

Collaborators

Detail Information

Publications5

  1. doi request reprint ZEB2, a new candidate gene for asplenia
    Linda Pons
    Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Génétique et Centre de référence des anomalies du développement, Bron F 69677, France
    Orphanet J Rare Dis 9:2. 2014
    ..Our report shows that spleen hypo/aplasia is part of the MWS phenotype and makes ZEB2 a possible candidate gene for primary asplenia. ..
  2. doi request reprint Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output
    Sophie Dupuis-Girod
    Hospices Civils de Lyon, Hopital Louis Pradel, Genetic Department and National Reference Center for Rendu Osler Disease, Bron, France
    JAMA 307:948-55. 2012
    ..Anti-vascular endothelial growth factor treatments such as bevacizumab may be an effective treatment...
  3. ncbi request reprint Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association
    Sophie Dupuis-Girod
    Service de Génétique et Centre de Référence sur la Maladie de Rendu Osler, hôpital de l Hôtel dieu, Lyon, France
    Clin Infect Dis 44:841-5. 2007
    ..Cerebral infections accounted for 33% of all infections, were mainly due to multiple and anaerobic bacteria, and were associated with the presence of pulmonary arteriovenous malformations and a short duration of epistaxis...
  4. doi request reprint Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study
    Sophie Dupuis-Girod
    Service de Génétique et Centre de Référence pour la Maladie de Rendu Osler, Lyon, France
    Liver Transpl 16:340-7. 2010
    ..In conclusion, OLT is an important therapeutic option for patients with HHT who have severe hepatic involvement. In the reported cohort, the mortality after OLT for this indication was low...
  5. doi request reprint Hereditary hemorrhagic telangiectasia: from molecular biology to patient care
    S Dupuis-Girod
    Service de Génétique et Centre de Référence National Maladies Rares, maladie de Rendu Osler, Hospices Civils de Lyon, hôpital de l Hôtel dieu, Lyon, France
    J Thromb Haemost 8:1447-56. 2010
    ....